Expert Interview
A discussion of EB-101 from Abeona Therapeutics as a potential autologous cell therapy in recessive dystrophic epidermolysis bullosa (RDEB)
Ticker(s): ABEO, KRYS, BBIOInstitution: Stanford
- Associate Professor of Dermatology and a faculty member of the Program in Epithelial Biology and the Stanford Cancer Biology Program.
- Research interest in inflammatory skin disease and is Director of the Stanford Bullous Disease and Psoriasis Clinics as well as an attending dermatologist at the VA Palo Alto Medical Center.
- Research focuses on pathogenesis and therapy of epidermolysis bullosa, autoimmune blistering diseases, psoriasis and skin cancer.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
